NCI-2022-06272

A first-in-human, phase 1/2, open-label, multi-center, dose-escalation and dose-expansion study to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity of the ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors

This is an early-stage, first-in-human medical study that aims to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of an investigational drug called MP964. MP964 is an ATR inhibitor, a type of drug that targets a protein involved in DNA damage repair in cancer cells. By inhibiting this protein, MP964 may be able to help kill cancer cells. The study is open to adults with advanced solid tumors who have not received prior treatment with an ATR inhibitor. The study will be conducted in two parts:

Part 1: This is a dose-escalation phase, where researchers will determine the safest and most effective dose of MP964.

Part 2: This is a dose-expansion phase, where researchers will further evaluate the safety and effectiveness of MP964 at the chosen dose from Part 1 in a larger group of patients. The study will also collect and analyze tumor tissue to understand how MP964 works.

Early-stage: Early phase (phases I and II) studies help researchers determine: Whether a new treatment is safe, what its side effects are and the best dose of the new treatment.

Advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05269316

NCI-2022-06272

Clinical Trial Site: Sinai

To see all available clinical trials click here.